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Colorectal cancer statistics
• Colorectal cancer (CRC) is the 3rd most common type of
cancer and 2nd cause of cancer-related death in the US
• In 2019, estimated new CRC 145,000, ~51,000 deaths
• Estimated that more than half of all cases can be prevented
by regular colonoscopy screening
• Lifetime risk 1 in 22
• CRC screening improved recently. 40%62% 2015. Goal
80%
American Cancer Society (2019)
https://cancerstatisticscenter.cancer.org

Cologuard
• FDA approved in 2014
• Stool based test which detects DNA mutations
• Non-invasive screening option done at home, available by
prescription only
• Detected 92% cancers, 69% HGD, 42% advanced adenomas
• FIT test: 74% cancers, 46% HGD, 24% advanced adenomas

• Medicare approved every 3 years, age 50-75, who are
asymptomatic, average risk (no hx prior polyps, ca, FH of ca
etc)

NEJM 2014

11

*

Conducted by Exact Sciences Staff
Cologuard’s patient compliance rate is derived from the number of completed tests reported divided by
the number of collection kits shipped to patients during the 12-month period ending 60 days prior to
December 31, 2016.

>92% of all Cologuard patients have no out of pocket cost for screening

Conclusion
• Screening tests offer the best way to prevent CRC or find
polyps early. Early detection allows for better chance for
successful treatment
• Early CRC usually has no symptoms. Do not wait for
symptoms to occur
• Treatment is most effective when CRC is found early
• Get appropriate screening for colorectal cancer!!!
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